Monday, June 27, 2022

50% Spike On Rich Pharmaceuticals Inc (OTCMKTS:RCHA)

Rich Pharmaceuticals Inc (OTCMKTS:RCHA) is seeing a 50% jump today. RCHA looks like a breakout candidate after its release that it is teaming up with Hypgen to tackle Parkinson’s disease. The deal was done three months ago but it looks like the market is just starting to add this into the price.
The stock has been seeing an increase and volume and we noted that RCHA had picked up approval for an investigational new drug (IND) application from the FDA related to its lead oncology asset. The drug in question is called RP-323 and, if it’s mechanism of action proves effective, it could be a real winner for both its target patient population and Rich and its shareholders going forward.
Rich Pharmaceuticals Inc (OTCMKTS:RCHA), according to company documents, is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology and other blood related diseases. RCHA’s goal is to extend refractory patients life expectancy and increase quality of life.
The company’s primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. RP-323 is a phorbol ester, which induces differentiation and/or apoptosis in multiple cell lines and primary cells, activates protein kinase C (PKC), and modulates the activity of multiple downstream cell signaling pathways, including mitogen-activated protein kinase (MAPK) pathways.
RP-323 induces PKC to produce NF kappa, which then produces NF kappa B that has the ability to regulate cellular responses by entering into the nucleus of cells. NF kappa B binds to DNA and changes the nature of the cell and (1) induces differentiation; (2) induces proliferation; (3) cytokine induction; (4) and/or apoptosis.
Find out when $RCHA stock reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

RCHA’s previous announcement, the partnership with Hypgen, also offered good news and might theoretically be even bigger reason for the increase in volume. “HypGen is commencing work on treatments for Parkinson’s disease. Certain of the data Rich Pharmaceuticals has amassed for its treatment protocol for Acute Myelocytic Leukemia (AML) will have significant value for HypGen as it moves forward in the regulatory process,” said Ben Chang, CEO, RCHA. “There is a long tradition in biotechnology to share data when possible because we all have the same aim: To save lives and to prolong productive lives. We are blessed to play a role in that tradition and pleased that our investors will benefit from this agreement,” Mr. Chang said.
Rich Pharmaceuticals Inc (OTCMKTS:RCHA) is a biotech to watch, but one that you need to know is still a long way off. Keep in mind, a few years back this stock was worth more than $30. So, we are advising caution until more data comes out. For continuing coverage on shares of $RCHA stock, as well as our other breakout stock picks, sign up for our free newsletter today and get our next hot stock pick!
Disclosure: we hold no position in $RCHA, either long or short, and we have not been compensated for this article.

Related Articles

Stay Connected


Latest Articles